Maturity-onset diabetes of the young (MODY) is often misdiagnosed as Type I or II diabetes. This study was designed to assess the cost-effectiveness of MODY screening strategies in Hungary, which included a recent genetic test compared with no routine screening for MODY. A simulation model that combined a decision tree and an individual-level Markov model was constructed to assess the costs per quality-adjusted life year of screening strategies. Stratifying patients based on age and insulin treatment followed by a risk assessment questionnaire, a laboratory test and genetic testing was the most cost-effective strategy, saving EUR 12 and generating 0.0047 quality-adjusted life years gained per screened patient. This screening strategy could be considered for reimbursement, especially in countries with limited resources.
CITATION STYLE
Kovács, G., Nagy, D., Szilberhorn, L., Zelei, T., Gaál, Z., Vellekoop, H., … Nagy, B. (2023). Cost-effectiveness of genetic-based screening strategies for maturity-onset diabetes of the young. Personalized Medicine, 20(4), 375–385. https://doi.org/10.2217/pme-2023-0023
Mendeley helps you to discover research relevant for your work.